This gene therapy startup has attracted the eye of investors, including a $13-million fundraising round announced in early December to help iVexSol expand from its space at Worcester’s Massachusetts Biomedical Initiatives incubator into a manufacturing site in Lexington.
That’s in addition to $2 million last year, along with $250,000 from the Massachusetts Life Science Center this year. Lots of startups toil for years before reaching the market, and though iVexSol isn’t there yet, the funding it’s attracted is a good sign. Gene therapy is seen as a major growth industry within biotech, with an ability to treat cancers and genetic disorders by changing the genetic make-up of cells in the body.
